CXL Ophthalmics, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
CXL Ophthalmics, Inc. - overview
Established
2012
Location
-, MA, US
Primary Industry
Healthcare
About
Based in Massachusetts, US, and founded in 2012, CXL Ophthalmics, Inc. operates as a healthcare company that provides medical devices to treat patients with keratoconus and corneal diseases. In September 2022, CXL Ophthalmics, Inc. raised USD 32 million in Series A funding from AXA IM Alts, with participation from individual investors.
As of October 2022, Michael D. Webb is the Chief Operating Officer (CEO) of the company. CXL Ophthalmics, Inc. treats patients having weakened cornea that changes its shape and degrades vision.
The company offers a device known as EpiSmartTM device, which provides proteins for the cornea to be strengthened by chemically cross-linking them and allowing patients to have better vision. The company plans to use the September 2022 funding to continue the advancement of its product called Epismart.
Current Investors
AXA IM Alts
Primary Industry
Healthcare
Sub Industries
Healthcare, Therapeutic Devices
Website
www.cxlophthalmics.com
Verticals
HealthTech, Manufacturing
Company Stage
Series A
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.